Literature DB >> 35698688

Modeling Amyotrophic Lateral Sclerosis Progression: Logic in the Logit.

Afaf Shaabi1.   

Abstract

Background Amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R) has emerged as a clinical prognostic marker for clinical and research purposes in amyotrophic lateral sclerosis (ALS). However, tools for predicting disease progression are still underdeveloped. The aim of this study was to mathematically model ALS progression to provide a reliable and personalized approach to the prognosis for ALS patients. Also, it aimed to provide a reliable prediction tool for the current and newly diagnosed patients. Methods Twenty patients from the South-East England Amyotrophic Lateral Sclerosis register (SEALS) database were included in the analysis. A non-linear logistic regression model was used to describe disease progression from baseline health to the theoretical maximum disease. The reliability of predicted variables and correlation between model parameters were assessed separately for each subject. Results The logistic regression model best described the disease progression in patients with a high progression rate. Most notably, the model fitted better when a patient has progressed enough to approximately the midpoint of the functional rating scale. The model failed to characterize the disease course in patients defined as slow progressors. Furthermore, the linear relationship between the rate of progression and time since onset at ALFRS-R score of 24 was evident in 65% of patients. Conclusion These results indicate that the rate of disease progression and time when ALSFRS-R declines to half the maximum score are correlated with functional outcomes. Nonetheless, the logistic model failed to describe disease course in patients with slow progression rates. Different rates of progression can be attributed to the genetic heterogeneity of ALS. Thus, clinicians and patients can benefit from adding a gene factor to the equation. With the outlined limitations, the model can provide a good prognostic tool.
Copyright © 2022, Shaabi et al.

Entities:  

Keywords:  alsfrs-r; amyotrophic lateral sclerosis; disease progression; mathematical modeling; neuro degenerative diseases

Year:  2022        PMID: 35698688      PMCID: PMC9183745          DOI: 10.7759/cureus.24887

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  21 in total

1.  Progression in ALS is not linear but is curvilinear.

Authors:  Paul H Gordon; Bin Cheng; Francois Salachas; Pierre-Francois Pradat; Gaelle Bruneteau; Philippe Corcia; Lucette Lacomblez; Vincent Meininger
Journal:  J Neurol       Date:  2010-06-08       Impact factor: 4.849

2.  The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study.

Authors:  Julie Phukan; Marwa Elamin; Peter Bede; Norah Jordan; Laura Gallagher; Susan Byrne; Catherine Lynch; Niall Pender; Orla Hardiman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-08-11       Impact factor: 10.154

Review 3.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

4.  Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.

Authors:  Koen Poesen; Maxim De Schaepdryver; Beatrice Stubendorff; Benjamin Gille; Petra Muckova; Sindy Wendler; Tino Prell; Thomas M Ringer; Heidrun Rhode; Olivier Stevens; Kristl G Claeys; Goedele Couwelier; Ann D'Hondt; Nikita Lamaire; Petra Tilkin; Dimphna Van Reijen; Sarah Gourmaud; Nadin Fedtke; Bianka Heiling; Matthias Rumpel; Annekathrin Rödiger; Anne Gunkel; Otto W Witte; Claire Paquet; Rik Vandenberghe; Julian Grosskreutz; Philip Van Damme
Journal:  Neurology       Date:  2017-05-12       Impact factor: 9.910

5.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors:  J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

6.  Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology.

Authors:  Mark H B Huisman; Sonja W de Jong; Perry T C van Doormaal; Stephanie S Weinreich; H Jurgen Schelhaas; Anneke J van der Kooi; Marianne de Visser; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-05-27       Impact factor: 10.154

7.  Measuring function in advanced ALS: validation of ALSFRS-EX extension items.

Authors:  P Wicks; M P Massagli; C Wolf; J Heywood
Journal:  Eur J Neurol       Date:  2009-03       Impact factor: 6.089

Review 8.  What causes amyotrophic lateral sclerosis?

Authors:  Sarah Martin; Ahmad Al Khleifat; Ammar Al-Chalabi
Journal:  F1000Res       Date:  2017-03-28

9.  Genetic correlation between amyotrophic lateral sclerosis and schizophrenia.

Authors:  Russell L McLaughlin; Dick Schijven; Wouter van Rheenen; Kristel R van Eijk; Margaret O'Brien; René S Kahn; Roel A Ophoff; An Goris; Daniel G Bradley; Ammar Al-Chalabi; Leonard H van den Berg; Jurjen J Luykx; Orla Hardiman; Jan H Veldink
Journal:  Nat Commun       Date:  2017-03-21       Impact factor: 14.919

Review 10.  Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis.

Authors:  Benoît Marin; Farid Boumédiene; Giancarlo Logroscino; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Massimilano Copetti; Pierre-Marie Preux; Ettore Beghi
Journal:  Int J Epidemiol       Date:  2017-02-01       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.